SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Cipla's arm recalling six batches of Albuterol Sulfate inhalation Aerosol in US

10 Jul 2023 Evaluate

Cipla's wholly-owned subsidiary -- Cipla USA Inc is voluntarily recalling the six batches of Albuterol Sulfate inhalation Aerosol 90 mcg, manufactured in November 2021, to the consumer level. The company is initiating a recall in the US due to a market complaint for one single inhaler (batch number - IB20056), where leakage was observed through the inhaler valve.

These six batches were distributed nationwide to wholesalers and retailers. The product is used for the treatment and prevention of bronchospasm with reversible obstructive airway disease and for the prevention of exercise induced bronchospasm.

Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients.


Cipla Share Price

1238.30 7.55 (0.61%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×